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Abstract: Axial spondyloarthritis (axSpA) is a chronic rheumatic disease characterized by the pres-
ence of inflammatory back pain. In patients with chronic low back pain, the lumbar flexion relaxa-
tion phenomenon measured by surface electromyography (sEMG) differs from that in healthy indi-
viduals. However, sEMG activity in axSpA patients has not been studied. The purpose of this study 
was to analyze the flexion relaxation phenomenon in axSpA patients. A study evaluating 39 axSpA 
patients and 35 healthy controls was conducted. sEMG activity at the erector spinae muscles was 
measured during lumbar full flexion movements. sEMG activity was compared between axSpA 
patients and the controls, as well as between active (BASDAI ≥ 4) and non-active (BASDAI < 4) 
patients. The reliability (using intraclass correlation coefficients (ICC)), criterion validity and discri-
minant validity using the area Under the curve (AUC) for the inverse flexion/relaxation ratio 
(1/FRR) were evaluated. Significant differences (p < 0.05) were observed between axSpA patients 
and the control group in lumbar electric activity, especially during flexion, relaxation, and extension 
and in FRR and 1/FRR (0.66 ± 0.39 vs. 0.25 ± 0.19, respectively). In addition, significant differences 
were found between active and non-active but also between non-active and healthy subjects. The 
sEMG showed good reliability (ICC > 0.8 for 1/FRR) and criterion validity. ROC analysis showed 
good discriminant validity for axSpA patients (AUC = 0.835) vs. the control group using 1/FRR. An 
abnormal flexion/relaxation phenomenon exists in axSpA patients compared with controls. sEMG 
could be an additional objective tool in the evaluation of patient function and disease activity status. 
Keywords: axial spondyloarthritis; surface electromyography (sEMG); flexion relaxation ratio; 
functional assessment; clinimetric properties 
 
1. Introduction 
Axial spondyloarthritis (axSpA) is a chronic, inflammatory, rheumatic disease with 
high phenotypic heterogeneity. It is characterized by new bone formation in the sacroiliac 
joints and axial skeleton. Inflammatory back pain (IBP) represents a clinical expression of 
lumbar spine inflammation, which leads to structural damage and a decrease in spinal 
mobility [1,2]. 
The concept of mechanical stress in the pathogenesis of axSpA has recently been re-
vitalized, with the theory that interactions between biomechanical factors and the innate 
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immune response may lead to the development of enthesitis [3,4]. This activation of met-
abolic pathways and cytokines would not be confined exclusively to entheses but would 
also involve tissues immediately adjacent to this organ: bone, fascia, extra enthesis, and 
the Synovio-Entheseal Complex (SEC) [5]. Some authors have reported pathological 
changes in the paravertebral muscles in axSpA patients (such as muscle fiber atrophy and 
cytoarchitectural abnormalities) [6,7], which could be associated with overactivity 
through their paravertebral muscles and altered load-sharing capability of the tissues [8]. 
These findings suggest that hypertonicity in the axSpA could involve an excess of joint 
forces associated with damage to the vertebral enthesis and raise the issue of whether this 
phenomenon is a cause or consequence of pathway activation and, therefore, of structural 
damage in axSpA patients [6,9]. 
Surface electromyography (sEMG) has been suggested as a useful objective tool in 
the assessment of musculoskeletal dysfunction associated with mechanical low back pain 
(LBP) [10,11]. The dynamic measurement of the sEMG activity in paraspinal muscles can 
be useful in differentiating between patients with LBP and asymptomatic subjects and to 
detect changes after treatment [12]. In maximum voluntary flexion (MVF), sEMG activity 
is often at or below the level of sEMG activity during standing [13]. However, in people 
with LBP, this paraspinal relaxation tends to be absent or decreased [14,15]. The flexion/re-
laxation (F/R) phenomenon is important because it enables the full expression of lumbar 
flexion to occur in normal subjects [16]. sEMG allows both a patient and clinician to have 
direct and immediate access to muscle functioning that is not possible with manual pal-
pation or visual observation [17]. A common factor used to evaluate the F/R phenomenon 
is the F/R ratio (FRR), as well as the inverse FRR (1/FRR) [18]. The latter is essentially the 
percentage to which the lumbar muscles become electrically silent during full flexion in 
comparison with the higher activity seen during forward flexion [18]. However, to our 
knowledge, the FRR has not been explored in axSpA patients. On the basis of the forego-
ing, the analysis of sEMG in the paravertebral musculature could be of interest due to its 
possible association with biomechanical stress and motor control in axSpA patients. Thus, 
in this study, we propose the first clinometric approach to sEMG activity in these patients, 
focusing on the FRR in axSpA patients and clinimetric properties with three goals: (a) to 
describe the activity and variability of sEMG in patients with axSpA; (b) to demonstrate 
the reliability of sEMG in axSpA patients and healthy subjects; and (c) to evaluate the 
validity of sEMG to distinguish not only between axSpA patients vs. healthy subjects but 
also between axSpA active patients vs. non-active patients. 
2. Materials and Methods 
2.1. Patients 
A total of 39 patients with axSpA, as determined by the Assessment of Spondyoar-
thritis International Society (ASAS) criteria [19], and 35 healthy controls were included in 
the study. Inclusion criteria for the patient group were as follows: (a) patients ages ≥ 18 
years with a clinical diagnosis of adult-onset axSpA of ≥3 months duration and (b) patients 
who met the ASAS classification criteria. Inclusion criteria for healthy controls were: (a) 
ages ≥ 18 years and (b) absence of LBP or IBP. Patients suffering from disc disease or who 
had undergone previous surgery were excluded from the two groups. 
Eligible participants (axSpA patients and controls) were scheduled for a physical ex-
amination, in which they completed questionnaires, were screened by study physicians, 
and underwent electromyography study. 
All patients signed a consent form, and the protocol was approved by the “Hospital 
Universitario Reina Sofía” Ethics Committee (Ref. 1393-N-16). 
2.2. EMG Recordings 
A surface electromyogram (sEMG) telemetry system (TELEMYO 2400T®; Noraxon 
USA Inc., 13,430 N. Scottsdale Rd., Suite 104, Scottsdale, AZ 85254, USA) was used. A 
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synchronised video recording (25 Hz) was performed using a video camera (SONY 
handycam DCR-HC23, Tokyo, Japan). The video was used to distinguish events in the 
sEMG signal. 
The methodology for the F/R test was based on the work of Watson et al. [14] Elec-
trodes were placed paraspinally (right and left lumbar erector spinae) at the L4–L5 level 
and separated at 2.5 cm from the spinous process. The reference electrode was placed on 
the spinous process at the L3 level, and the sensors were oriented so that they were paral-
lel to the muscle fibers (Figure 1). The skin underlying the electrode was cleaned with 
cotton soaked in alcohol to provide a better conductivity. 
Participants were instructed to move from a standing position to full frontal flexion 
in a gentle manner for 10 s. Full flexion was maintained for 5 s, followed by a return to the 
vertical position for another 10 s. After a rest of 5 s, the complete movement was repeated. 
Two cycles were recorded to calculate variability between measurements. 
 
Figure 1. Electrodes placement. 
2.3. Data Reduction 
Prior to study and interpretation, the electromyographic signals were processed 
(Noraxon Myoresearch® XP, Noraxon USA, Scottsdale, AZ, USA), applying some filters: 
rectification, smoothing (RMS-500 ms window), and finally a 10 Hz Butterworth low-pass 
filter. The sEMG signal was divided into phases based on the time points identified in the 
channel position data. The phases were identified as standing, flexion, relaxation, and ex-
tension. 
2.4. Variables 
Sociodemographic (age, sex) and anthropometric data (weight, height, and body 
mass index (BMI)) were collected for both groups (axSpA patients and controls). All sub-
jects also underwent sEMG. During sEMG, the patient started in a standing position, and 
he/she performed a sequence of a flexion movements, relaxation (or full flexion), exten-
sion, and a return to standing (Figure 2). 
  




Figure 2. sEMG activity and results obtained by a healthy subject and an axSpA patient. 
The lumbar muscle electric activity measured in μV was obtained in each phase. In 
addition, the FRR was calculated considering the maximum value of sEMG during flexion 
divided by the value during relaxation (full flexion). The inverse FRR (1/FRR) was also 
calculated, which has the advantage of providing a normalised sEMG factor, which makes 
it possible to compare sEMG factors over time and across individuals [14,18]. Values for 
1/FRR typically range from 0 to 1 since sEMG activity is normally lower during relaxation 
(full flexion) than during flexion movement. When 1/FRR is 1, sEMG activity during flex-
ion and relaxation would be the same (no silence at all). Figure 2 shows an example of 
sEMG activity in each phase of the movement for an individual healthy subject and a pa-
tient. In a healthy subject, the typical pattern shows high electric activity during flexion, a 
silent phase during relaxation or full flexion, and high electric activity during extension, 
with a 1/FRR near 0. In case of absence of silent phase, the 1/FRR would be near 1. 
Four variables were completed by the axSpA group, which served as criterion valid-
ity: function index was measured with the Bath Ankylosing Spondylitis Functionality In-
dex (BASFI) [20]; disease activity was measured with the Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI) [21]. Mobility was defined according to J. Sieper’s re-
view [2]: cervical rotation, tragus-wall distance, lateral spinal flexion, modified Schöber 
test, intermaleolar distance and the Bath Ankylosing Spondylitis Metrology Index 
(BASMI) [22]. 
A rheumatologist (I.C. AV) experienced in the use of the sEMG device and in con-
ventional metrology performed the entire patient measurement process. 
2.5. Statistical Analysis 
The sample size estimation was calculated so that mean effect sizes of 0.3 could be 
detected with a power of 80% and a risk α of 5%. 
Descriptive data are presented as the mean ± standard deviation (SD) for qualitative 
variables and as frequencies and percentages for qualitative variables. A p-value < 0.05 
was considered significant, and the statistical analysis was performed using IBM SPSS 
software (version 17.0) and R statistical language R Studio (version 1.1.383). 
First, demographic and anthropometric data between axSpA patients and the healthy 
group were compared to verify that both groups were similar. 
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Second, the average values of sEMG measurements were compared between axSpA 
patients vs. the control group, between active axSpA vs. non-active axSpA (defining active 
and non-active patients as a BASDAI ≥ 4 or BASDAI < 4, respectively), and between non-
active axSpA vs. controls by using a Student’s t test for independent samples. 
The clinimetric proprieties of the 1/FRR were evaluated according the COnsensus-
based Standards for the Selection of health status Measurement INstruments (COSMIN) 
[23]. 
2.5.1. Reliability 
The internal consistency of the measurements was evaluated in all patients through 
the use of an intraclass correlation coefficient (ICC). Measurement errors were calculated 
using standard deviation. 
2.5.2. Criterion Validity 
To determine factors associated with sEMG in axSpA patients, Pearson’s linear cor-
relations were performed between sEMG data and conventional scores, BASDAI, BASFI, 
and BASMI. 
2.5.3. Discriminant Validity 
Four receiver operating characteristic (ROC) curves analyses (axSpA vs. controls, ac-
tive axSpA vs. non-active axSpA, non-active axSpA vs. controls and active axSpA vs. con-
trols) evaluated the validity of 1/FRR to distinguish between axSpA patients and healthy 
subjects and between axSpA active patients vs. non-active patients. 
3. Results 
Among the 74 subjects (39 axSpA and 35 healthy) included in the study, 56 (75.7%) 
were men, and the average age was 44 ± 10.2 years (Table 1). There were no significant 
differences between the groups in terms of age, sex, weight, height, or BMI (Table 1). 
Table 1. Demographics data in both groups. 
Demographic Data axSpA Group 
n = 39 
Control Group 
n = 35 
p 
Age (±SD) years 46 (8.06) 42 (11.89) 0.115 
Sex (%) men 29 (74.4%) 27 (77.1%) 0.780 
women 10 (25.6%) 8 (22.9%)  
Weight (±SD) kg 80.4 (17.2) 78.9 (16.1) 0.702 
Height (±SD) m 1.7 (0.6) 1.7 (0.8) 0.197 
BMI (SD) 27.6 (5.8) 26.1 (3.8) 0.211 
BMI: Body Mass Index. SD: Standard Deviation. 
3.1. sEMG Measurements between axSpA and Controls 
No significant differences appeared between the right nor left sides of the sEMG 
measurements, so mean values were considered for the analysis (data not shown). 
Table 2 shows the average values in μV of each sEMG measure. Significantly reduced 
electric activity was observed between axSpA patients vs. the control group during flexion 
(20.38 ± 11.62 vs. 36.50 ± 20.09) and extension (39.07 ± 23.45 vs. 66.09 ± 15.53), and increased 
electric activity was observed during relaxation (or full flexion) (13.08 ± 11.69 vs. 6.87 ± 
4.02). In addition, a reduced FRR was found among axSpA vs. controls (2.40 ± 1.89 vs. 7.13 
± 6.64), meaning that the electric activity during flexion and relaxation was similar among 
axSpA patients and that controls had a decrease in electric activity during full flexion (si-
lent phase). Similarly, an increased 1/FRR was found in axSpA patients vs. controls (0.66 
± 0.39 vs. 0.25 ± 0.19). 
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3.2. sEMG Measurements between Active axSpA and Non-Active axSpA 
When patients were grouped into active axSpA (BASDAI ≥ 4, n = 22) vs. non-active 
axSpA (BASDAI < 4, n = 17) (Table 2), we found that active patients showed lower values 
of EMG signals in standing (6.59 ± 2.18 vs. 10.47 ± 5.19) and extension (23.38 ± 12.40 vs. 
46.49 ± 23.28), lower FRR (1.51 ± 1.05 vs. 3.11 ± 2.11), and a higher score in 1/FRR (0.82 ± 
0.31 vs. 0.57 ± 0.42) against non-active axSpA patients. We also compared non-active 
axSpA patients vs. the control group, and we found a significant decrease in electric ac-
tivity in flexion and extension, a lower FRR and a higher 1/FRR in non-active axSpA pa-
tients. 
Table 2. Average values in each phase by group, significant differences, and reliability results. 
 
axSpA 
n = 39 
Control 
n = 35 p (1) 
Active 
axSpA 
n = 22 
Non Active 
axSpA 
n = 17 
p (2) p (3) ICC 
FRR 2.40 (1.89) 7.13 (6.64) *** 1.51 (1.05) 3.11 (2.11) ** ** 0.682 
1/FRR 0.66 (0.39) 0.25 (0.19) *** 0.82 (0.31) 0.57 (0.42) ** ** 0.938 
Flx/Ext 0.60 (0.32) 0.59 (0.39) N.S. 0.67 (0.30) 0.57 (0.34) N.S. N.S. 0.560 
Standing 9.35 (4.92) 9.57 (4.20) N.S. 6.59 (2.18) 10.47 (5.19) ** N.S. 0.840 
Flexion 20.38 (11.62) 36.50 (20.09) *** 16.96 (10.86) 21.20 (11.37) N.S. *** 0.817 
Relaxation 13.08 (11.69) 6.87 (4.02) ** 14.60 (11.59) 10.54 (10.94) N.S. N.S. 0.631 
Extension 39.07 (23.45) 66.09 (25.53) *** 23.48 (12.40) 46.49 (23.28) *** ** 0.927 
Mean values (SD) of EMG signals in μV. FRR: flexion-relaxation ratio; 1/FRR: inverse flexion-relax-
ation ratio; Flx/Ext: flexion-relaxation index. Active axSpA: BASDAI >= 4. Non Active axSpA: 
BASDAI < 4. Student t test Differences: (1) axSpA/Control (2) Active/Non Active (3) Non Ac-
tive/Control. ** p < 0.01; *** p < 0.001, N.S.: Not significant. 
3.3. Reliability 
The reproducibility of these measurements was evaluated in all patients with the 
ICCs (Table 2). Standing, flexion, extension and 1/FRR measures showed excellent inter-
rater agreement (ICC > 0.8), while relaxation and FRR showed good agreement (ICC > 0.6). 
3.4. Criterion Validity 
Pearson correlations for age, function, disease activity and mobility in the axSpA 
group are shown in Table 3. Index 1/FRR showed a strong negative linear relationship 
with lateral flexion (r = −0.71), a moderate negative correlation with the Schöber measure 
(r = −0.55), and a moderate positive linear correlation with the BASFI (r = 0.52) and BASMI 
(r = 0.65). These results showed that an increment in 1/FRR (i.e., absence of silent phase 
during relaxation or similar electric activity during flexion and relaxation) in axSpA pa-
tients is associated with poorer mobility (i.e., less lateral flexion, less Schober, and higher 
BASMI) as well as poorer function (higher BASFI). 
Table 3. Correlations between sEMG measures and other variables for axSpA group. 
 Age Lat. Flex. Schober Cerv. Rot. BASDAI BASFI BASMI 
FRR −0.19 0.60 *** 0.53 *** 0.26 −0.39 * −0.44 ** −0.59 *** 
1/FRR 0.27 −0.71 *** −0.55 *** −0.27 0.38 * 0.52 *** 0.65 *** 
Flx/Ext 0.05 −0.40 * −0.45 ** 0 0.19 0.12 0.39 * 
Standing 0.02 0.16 −0.1 0.17 −0.35 * −0.23 −0.15 
Flexion −0.01 0.24 −0.08 0.18 −0.26 −0.28 −0.18 
Relaxation 0.18 −0.24 −0.40 * −0.1 0.14 0.15 0.29 
Extension −0.1 0.60 *** 0.31 0.43 ** −0.50 ** −0.47 ** −0.60 *** 
FRR: flexion-relaxation ratio; 1/FRR: inverse flexion-relaxation ratio; Flx/Ext: flexion-relaxation 
index. * p < 0.05; ** p < 0.01; *** p < 0.001. 
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3.5. Discriminant Validity 
Figure 3 shows results of the four ROC analyses (axSpA vs. controls, active axSpA 
vs. non-active axSpA, non-active axSpA vs. controls and active axSpA vs. controls) re-
garding 1/FRR. A cut-off of 0.3 in the 1/FRR measure revealed an AUC of 0.835 when 
comparing axSpA patients vs. the control group, with a sensitivity of 77.1% and a speci-
ficity of 74.4% (Figure 3a). This index also produced useful results for distinguishing be-
tween active and non-active axSpA (AUC = 0.708) and between non-active axSpA and 




axSpA/Control Active axSpA/Non active axSpA 
  
Non active axSpA/Control Active axSpA/Control 
Figure 3. ROC analysis using 1/FRR to distinguish axSpA patients and healthy controls. 
4. Discussion 
To our knowledge, this is one of the first studies aiming to evaluate flexion/relaxation 
phenomena in axSpA patients. Our results highlight that an abnormal flexion/relaxation 
phenomenon (measured by FRR and 1/FRR) exists in axSpA patients compared with con-
trol subjects, suggesting the absence of a silent phase during relaxation or similar electric 
activity during flexion and relaxation in these patients. 
In our study, the FRR in axSpA patients was similar to that found by Watson et al. 
[14] in a sample of chronic LBP patients. This F/R phenomenon and its subsequent reduc-
tion in FRR in LBP patients have been described in the literature. Geisser et al. [24] found 
a relationship between fear of movement in the context of pain and loss of flexion relaxa-
tion in LBP patients, and other authors explained trunk motor control and its dysfunction 
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in patients with LBP using sEMG [25,26]. A loss of F/R might also contribute to the con-
version of back pain from acute to chronic. When muscles cannot relax normally, they will 
fatigue more quickly, leading to co-contraction of other trunk muscles to help maintain 
spinal stability [27]. This could be justified by possible changes in the predominance of 
muscle fibre types in the lumbar region; in this sense, it has been reported that chronic 
low back pain produces a conversion of type 1 muscle fiber to type 2 that are more fa-
tigued [7]. 
It has been suggested that paravertebral muscle atrophy and fibrosis in axSpA are 
the final consequences of the progressive disuse secondary to axial joint dysfunction 
caused by arthrodesis and spinal ankylosis [28]. However, another phenomenon could be 
added to this muscle involvement in axSpA. In muscle biopsies of patients with axSpA, 
atrophy, fibrosis and pathological cytoarchitectural changes in muscle fibers (core, multi-
core, core-targetoid, and moth-eaten) occur [6,29]. Although these changes in muscle pa-
thology are usually nonspecific, they occur experimentally after tenotomy and are inter-
preted as the adaptative response of muscle fibers to their shortening in length as a con-
sequence of tendon injury [30,31]. In addition, a reduction in the size of the muscle fibers 
occurs together with an increase in connective tissue, which is understood by the struc-
tural continuity of the extracellular matrix or muscular connective tissue with the tendon 
and the periosteum known as the fascial system. This system seems to act in an integrated 
way; therefore, an injury produced in a given territory can generate an adaptive or patho-
logical response in a related structure not limited to the injured tissue [32,33]. This struc-
tural response would justify the rigidity of muscles in the axSpA patients and the sEMG 
results. In this type of study, it is common to refer to the area when we measure the sEMG. 
We say that we measure the activity of erector spinae, although it is a combination of three 
muscles (iliocostal, longissimus y spinalis) that cannot completely separated. 
In this analysis, we also confirmed the reliability and concordance of sEMG measures 
(especially with the 1/FRR index), not only in axSpA patients but also in healthy subjects. 
We also demonstrated that the variability of FRR and 1/FRR in axSpA patients is directly 
associated with disease activity, functionality, and mobility, as measured by BASDAI, 
BASFI and BASMI, respectively. This prompted us to think that the disease status and 
physical condition of the patient could act as a cause or consequence for the loss of the F/R 
phenomenon, which could be demonstrated with further longitudinal analysis. This al-
teration in the F/R phenomenon has also been associated with LBP disability scores in 
previous studies [14,18,31]. 
Regarding the validity of the sEMG, our study shows that a value of 0.3 in 1/FRR has 
the predictive ability to discriminate axSpA patients from normal subjects, indicating that 
an important alteration in EMG activity exists in these patients. Interestingly, a good AUC 
was also found when comparing active vs. non-active axSpA patients, which means that 
this could be an additional tool to evaluate disease activity in patients. Finally, as ex-
pected, the greatest AUC was observed between active axSpA patients vs. the control 
group, i.e., between patients with high levels of inflammation and pain and healthy sub-
jects. 
Our study has some limitations but also several strengths. One limitation is that we 
did not include patients with mechanical LBP to be compared with axSpA patients. How-
ever, this was not the goal of our study. We conducted a first approach in axSpA patients, 
not patients in the whole group of spine diseases, even though this studies comparing 
sEMG in IBP patients against mechanical LBP are ongoing in our department. The sensi-
tivity and specificity of sEMG could be increased by using multiple measures. Although 
some authors indicate that sEMG is not usable in daily clinical practice (especially in the 
field of neurology) [34], many others currently contradict this statement [35,36] as sensor 
technology advances. Further research is needed to determine the combination of 
measures that are cost-effective and prospectively validated as a classification scheme. 
Another limitation is the small sample size included in our study. However, this was cal-
culated during the project design with a sufficient power to detect differences between 
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groups. The main strength of this study is that it is the first to evaluate sEMG activity in 
axSpA patients; thus, this could be the first step in the evaluation of sEMG and hyperto-
nicity in this pathology. 
5. Conclusions 
This study demonstrates that an abnormal flexion/relaxation phenomenon exists in 
axSpA patients and that sEMG could be an additional objective tool in the evaluation of 
patient functionality and disease activity status. 
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